The NeoAg Summit is the only industry-dedicated meeting focused on the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.
Neoantigen-targeted therapies are fast becoming the hottest area in personalized immunotherapies. With significant breakthroughs in technology, join us as we optimize the discovery and prediction of neoantigens, accelerating the industry to advance into clinic and effectively target tumor indications.
At the NeoAg Summit, we bring together the leading pharma and biotech companies to discuss:
- Advance neoantigen prediction approaches
- Improve immunogenicity and learn combination strategies
- Scale manufacture to improve the commercial potential of personalized therapies
Join the leaders from Genocea, Gritstone, Neon Therapeutics, Ziopharm Oncology, Parker Institute for Cancer Immunotherapy, La Jolla Institute for Allergy and Immunology and many more to spur on more efficacious personalised cancer vaccines and cell therapies.
November 20-22, 2019
+1 617 455 4188
Conference + Bootcamp: USD 3997.0,
Conference + 2 Workshops (A and B): USD 3997.0,
Conference + 1 Workshop (A or B): USD 3398.0,
Conference Only: USD 2799.0,
Workshops (Individual): USD 699.0
Speakers: Jessica Flechtner, CSO, Genocea, Andrew Allen, CEO, Gritstone, Stephen Schoenberger, Center Head, Professor, Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, Richard Gaynor, President of RandD, Neon Therapeutics, Fred Ramsdell, VP of Research, Parker Institute for Cancer Immunotherapy, Laurence Cooper, CEO, Ziopharm Oncology